



S. Lembke<sup>1</sup>, A. Weiß<sup>1</sup>, H. Marzo-Ortega<sup>2</sup>, A. Georgi<sup>1</sup>, D. Poddubnyy<sup>3</sup>, F. Behrens<sup>4</sup>, X. Baraliakos<sup>5,6</sup>, F. Proft<sup>7</sup> and A.C. Regierer<sup>1</sup>

<sup>1</sup>German Rheumatology Research Center, Program area Epidemiology and Health Services Research, Registry Research in Rheumatology, Berlin, Germany, <sup>2</sup>NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, <sup>3</sup>Division of Rheumatology, University of Toronto and Schroeder Arthritis Institute, University Health Network, Toronto, Canada, <sup>4</sup>University Hospital Frankfurt, Fraunhofer Institute ITMP, Rheumatology, Frankfurt, Germany, <sup>5</sup>Ruhr Universität, Bochum, Germany, <sup>6</sup>Rheumazentrum Ruhrgebiet, Herne, Germany, <sup>7</sup>Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany



EULAR 2026 – POS0472

Dr. Stephanie Lembke stephanie.lembke@drfz.de www.rabbit-spa.de

## AIM

To test the applicability of the

- EULAR Difficult-to-Manage (D2M) [1] and
- GRAPPA Complex-to-Manage (C2M) [2] and Treatment Refractory (TR) definitions

and to determine the frequency of PsA patients fulfilling these definitions in the German RABBIT-SpA registry

## METHOD

Inclusion criteria


- b/tsDMARD-naïve at registry entry
- ≥12 months follow-up (min. required to observe 2 treatment failures)

## CONCLUSIONS

Applying the recent EULAR and GRAPPA definitions to a large real-world cohort enabled the identification of clinically meaningful PsA subgroups (D2M, C2M, TR). Both frameworks proved feasible using routine rheumatology data and may help differentiate PsA phenotypes with varying therapeutic complexity.

## REFERENCES

1. Marzo-Ortega H et al. EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. *Ann Rheum Dis.* 2025.
2. Proft F et al. Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative. *Nat Rev Rheumatol.* 2025.



## RESULTS

